Intuitive Surgical is trading at $420.28, down 4.05%, as investors weigh planned pricing actions that could reduce instrument and accessory revenue per procedure.
- On October 21, the company said pricing actions could reduce instrument and accessory revenue per procedure by 3%–5% once fully implemented.
- U.S. da Vinci procedure growth was 10%; Intuitive Surgical narrowed its 2026 procedure-growth outlook to 14%–15%.
- The after-hours decline was linked to pricing and margin concerns despite an earnings beat.